Yahoo!
My Yahoo!
Mail
Sign In
[New User?
Sign Up
]
Finance Home
|
Help
Wednesday, February 10, 2010, 5:51pm SGT - The Singapore stock market is closed.
To create a watchlist or portfolio of shares,
Register
FINANCE HOME PAGE
INVESTING
FINANCE NEWS
Enter symbol(s):
Market:
Singapore
US
----------------
Argentina
Australia
Austria
Brazil
Canada - Toronto
Canada - Vancouver
China - Shanghai
China - Shenzhen
Denmark
France
Germany XETRA
Germany - Berlin
Hong Kong
India - Bombay
India - National
Indonesia
Israel
Italy
Korea
Korea - KOSDAQ
Malaysia
Mexico
Netherlands
New Zealand
Norway
Spain
Sweden
Switzerland
Taiwan OTC
Taiwan
Thailand
United Kingdom
Search by Company
|
Alphabetical List
Ardea Biosciences, Inc. (RDEA)
At 5:00AM SGT:
14.56 USD
0.00 (0.00%)
MORE ON RDEA
Quotes
Summary
Options
Historical Prices
Charts
Basic Chart
Technical Chart
News & Info
Headlines
Company Events
Company
Profile
Key Statistics
SEC Filings
Competitors
Industry
Analyst Coverage
Analyst Opinion
Analyst Estimates
Research Reports
Star Analysts
Ownership
Insider Trans.
Insider Roster
Financials
Income Statement
Balance Sheet
Cash Flow
Ardea Biosciences, Inc.
(NGM:RDEA) Delayed quote data
Last Trade:
14.56 USD
Trade Time:
5:00AM SGT
Change:
0.00 (0.00%)
Prev Close:
14.56
Open:
N/A
Bid:
N/A
Ask:
N/A
1y Target Est:
22.83
Day's Range:
N/A - N/A
52wk Range:
8.78 - 21.35
Volume:
0
Avg Vol
(3m)
:
104,554
Market Cap:
268.12M
P/E
(ttm)
:
N/A
EPS
(ttm)
:
-2.14
Div & Yield:
N/A (N/A%)
1d
5d
3m
6m
1y
2y
5y
max
Use Y! Toolbar to track stocks
Add RDEA to Portfolio
Download Data
HEADLINES
Ardea Biosciences names Felix Baker to board
AP
(Wed 2:08am)
ARDEA BIOSCIENCES, INC./DE Files SEC form 8-K, Change in Directors or Principal Officers
EDGAR Online
(Tue 9:45pm)
Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
PR Newswire
(Tue 9:30pm)
Ardea Biosciences to Present at the 12th Annual BIO CEO and Investor Conference
PR Newswire
(Fri, Feb 5)
Coverage initiated on Ardea Biosciences by Soleil
Briefing.com
(Thu, Jan 28)
ARDEA BIOSCIENCES, INC./DE Files SEC form 8-K, Regulation FD Disclosure
EDGAR Online
(Mon, Jan 11)
Ardea Biosciences rises on gout drug study results
AP
(Fri, Jan 8)
ARDEA BIOSCIENCES, INC./DE Files SEC form 8-K, Regulation FD Disclosure
EDGAR Online
(Thu, Jan 7)
Ardea Biosciences Reports Positive Results for RDEA594, its Lead Product Candidate for Gout, in Combination with Allopurinol or Febuxostat
PR Newswire
(Thu, Jan 7)
ARDEA BIOSCIENCES, INC./DE Files SEC form 8-K, Entry into a Material Definitive Agreement
EDGAR Online
(Wed, Dec 23)
More Headlines for RDEA...
ANALYST
EPS Est (next year)
(Dec-09)
:
-1.63
EPS Est (in 2 years)
(Dec-10)
:
-1.75
Avg Rec (current)*:
1.3
PEG Ratio:
N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion
-
Estimates
BUSINESS SUMMARY
Ardea Biosciences, Inc., a biotechnology company, focuses on the discovery and development of small-molecule therapeutics for the treatment of gout, human immunodeficiency virus (HIV), cancer, and inflammatory diseases in the United States.
Full Company Profile
Add to Portfolio
Email to a Friend
Get
Summary
for Another Symbol:
Singapore
US
----------------
Argentina
Australia
Austria
Brazil
Canada - Toronto
Canada - Vancouver
China - Shanghai
China - Shenzhen
Denmark
France
Germany XETRA
Germany - Berlin
Hong Kong
India - Bombay
India - National
Indonesia
Israel
Italy
Korea
Korea - KOSDAQ
Malaysia
Mexico
Netherlands
New Zealand
Norway
Spain
Sweden
Switzerland
Taiwan OTC
Taiwan
Thailand
United Kingdom
Search by Company
Latest News
Singapore Indices